TriSalus Life Sciences, Inc. (TLSI)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
Innovative Drug Delivery Technology and Immune-oncology Therapeutics	18.51M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
United States	18.51M